Literature DB >> 23901805

Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease.

Chengyan Xu1, Wei Ding, Minmin Zhang, Yong Gu.   

Abstract

AIM: Angiotensin-(1-7) (Ang-(1-7)) opposes angiotensin-II-induced cell growth, matrix accumulation and fibrosis in cardiac tissue. However, the role of Ang-(1-7) in the pathogenesis of renal fibrosis is uncertain. This study observed the effects of Ang-(1-7), on its own or in combination with losartan, an angiotensin-receptor blocker, on five-sixths nephrectomized rats.
METHODS: Male Sprague-Dawley rats underwent five-sixths nephrectomy, and then were either untreated, treated with Ang-(1-7), treated with losartan, or treated with a combination therapy of Ang-(1-7) and losartan. After 8 weeks, renal function was assessed by measuring systolic blood pressure, serum creatinine and proteinuria. The effect of nephrectomy on the renin-angiotensin system was examined by measuring plasma levels of Ang-II and Ang-(1-7). The extent of glomerulosclerosis and tubulointerstitial fibrosis was assessed by periodic acid-Schiff staining and Masson-trichrome staining. The expression of plasminogen activator inhibitor-1, fibronectin and angiopoietins-Tie-2 was investigated by immunohistochemistry and western blot.
RESULTS: In the groups of treated rats, serum creatinine, proteinuria and markers of glomerulosclerosis, such as fibronectin and plasminogen activator inhibitor-1, were ameliorated compared with the untreated, nephrectomized rats. Plasma Ang-(1-7) levels were elevated in all treatment groups, but the plasma Ang-II levels were reduced in the Ang-(1-7)-treated group and the combination therapy group. The ratio of Ang-1/Ang-2 was increased in the combination therapy group compared with two other treatment groups.
CONCLUSION: Ang-(1-7) ameliorated the renal injury of nephrectomized rats. The combination of Ang-(1-7) treatment alongside losartan exerted a superior effect to that of Ang-(1-7) alone on regression of glomerulosclerosis.
© 2013 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  angiogenesis; angiotensin; chronic kidney disease

Mesh:

Substances:

Year:  2013        PMID: 23901805     DOI: 10.1111/nep.12146

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  6 in total

Review 1.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

2.  Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort.

Authors:  Carmen Wolke; Alexander Teumer; Karlhans Endlich; Nicole Endlich; Rainer Rettig; Sylvia Stracke; Beate Fiene; Simone Aymanns; Stephan B Felix; Anke Hannemann; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-30

3.  Allicin inhibits tubular epithelial-myofibroblast transdifferentiation under high glucose conditions in vitro.

Authors:  Hong Huang; Fenping Zheng; Xuehong Dong; Fang Wu; Tianfeng Wu; Hong Li
Journal:  Exp Ther Med       Date:  2016-11-18       Impact factor: 2.447

4.  Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?

Authors:  Ranjit Singh Padda; Yixuan Shi; Chao-Sheng Lo; Shao-Ling Zhang; John S D Chan
Journal:  J Diabetes Metab       Date:  2015-10-14

5.  Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.

Authors:  Louise M Burrell; Daniel Gayed; Karen Griggs; Sheila K Patel; Elena Velkoska
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

6.  Angiotensin-(1-7) Attenuates Kidney Injury Due to Obstructive Nephropathy in Rats.

Authors:  Chang Seong Kim; In Jin Kim; Eun Hui Bae; Seong Kwon Ma; JongUn Lee; Soo Wan Kim
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.